Questcor Pharmaceuticals, Inc. (QCOR)

February 18, 2009

FeaturedProfiles.com Stock Pick: Questcor Pharmaceuticals, Inc. (QCOR)

Stock Price: $7.27

Questcor Pharmaceuticals, Inc. is a pharmaceutical company that markets two commercial products, H.P. Acthar® Gel (``Acthar'') and Doral®. Acthar (repository corticotropin injection) is an injectable drug that is approved for the treatment of certain disorders with an inflammatory component. Doral is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.

QCOR will be reporting fourth quarter earnings on Tuesday, February 24th after the close. QCOR has grown revenue from $12.78 million in 2006 to $49.76 million in 2007 and has reported revenue of $68.23 million during the first three quarters of 2008.

QCOR has high profit margins built into their business. QCOR's net income over the last three quarters has come in at $24.29. QCOR is trading at a PE of only around 10 and has a market cap of less than $500 million.

QCOR has been in an uptrend since the beginning of February and could break out in the near future. Its chart is looking attractive with its 50-day moving average right above at $7.58.








			February 18, 2009 FeaturedProfiles.com Stock Pick: Questcor Pharmaceuticals, Inc. (QCOR) Stock Price: $7.27 Questcor Pharmaceuticals, Inc. is a pharmaceutical company that markets two commercial products, H.P. Acthar® Gel (``Acthar'') and Doral®. Acthar (repository corticotropin injection) is an injectable drug that is approved for the treatment of certain disorders with an inflammatory component. Doral is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. QCOR will be reporting fourth quarter earnings on Tuesday, February 24th after the close. QCOR has grown revenue from $12.78 million in 2006 to $49.76 million in 2007 and has reported revenue of $68.23 million during the first three quarters of 2008. QCOR has high profit margins built into their business. QCOR's net income over the last three quarters has come in at $24.29. QCOR is trading at a PE of only around 10 and has a market cap of less than $500 million. QCOR has been in an uptrend since the beginning of February and could break out in the near future. Its chart is looking attractive with its 50-day moving average right above at $7.58.
			DISCLAIMER & RISK DISCLOSURE: FeaturedProfiles.com and SpeculatingStocks.com, Inc. and our affiliates ("our companies") are not registered investment advisers or broker/dealers. Our companies make no commitment that the purchase of securities of companies profiled or otherwise mentioned in our websites are suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the possible lack of liquidity for their securities, investing in such securities is highly speculative and carries a high degree of risk. Never invest based solely on information from this Web site or our email alerts. Our FeaturedProfiles.com Newsletter is our free alert email membership. We profile selected companies on our site. These companies compensate SpeculatingStocks.com, Inc. for profile coverage. This compensation can be found in the disclosure on the bottom of the page of profiles. This Disclaimer & Risk Disclosure is also at the bottom of profiles. Specific questions on membership or profiles can be obtained by writing the FeaturedProfiles.com at: staff@featuredprofiles.com.